Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

BACKGROUND: Most phase 3 clinical trials of systemic therapy for first-line unresectable hepatocellular carcinoma (HCC) have failed, with the exception of SHARP, REFLECT, and IMbrave150. We conducted indirect comparisons of therapies evaluated for first-line HCC treatment. SUMMARY: We conducted a sy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Liver Cancer
Main Authors: Vogel, Arndt, Rimassa, Lorenza, Sun, Hui-Chan, Abou-Alfa, Ghassan K., El-Khoueiry, Anthony, Pinato, David J., Sanchez Alvarez, Javier, Daigl, Monica, Orfanos, Panos, Leibfried, Michael, Blanchet Zumofen, Marie-Hélène, Gaillard, Vincent E., Merle, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2021
Assuntos:
Meta-Analysis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8237801/
https://ncbi.nlm.nih.gov/pubmed/34239810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000515302
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados